col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Publishing House: The Japanese Pharmacological Society

39 Results       Page 1

 [1] 
  original article Journal Date Title Authors All Authors
1 [GO] Folia Pharmacologica Japonica 2022―Jun―30 Treatment of COVID-19 Kazuhiro Yatera
2 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 Therapeutic effects of angiotensin converting enzyme 2 (ACE2) enzyme activity on acute lung injury in COVID-19 Tomokazu Yamaguchi, Midori Hoshizaki, Takafumi Minato, Satoru Nirasawa, Masamitsu Asaka, Mayumi Niiyama, et al. (+9)
3 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 Development of Therapeutics for HIV/AIDS, CHB and COVID-19 Hiroaki Mitsuya
4 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 Development of vaccines and therapeutics for COVID-19. Kiyama Ryuichi
5 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 A new approach to combat the sepsis including COVID-19 by accelerating detoxification of hemolysis-related DAMPs Daiki Ousaka, Dengli Wang, Masahiro Nishiboli
6 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 Human iPSC-based models to evaluate COVID-19 drugs Yasunari Kanda
7 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 PMDA's efforts to promote medical innovation in the coronavirus pandemic Yasuhiro Fujiwara
8 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 The coronavirus-related signaling pathway networks and prediction modeling with activity plots. Shihori Tanabe, Sabina Quader, Ryuichi Ono, Horacio Cabral, Kazuhiko Aoyagi, Akihiko Hirose, et al. (+2)
9 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 Eco-pharma research focusing on ACE2-mediated SARS-CoV-2 entry Kato Yuri, Yasunari Kanda, Motohiro Nishida
10 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 Characteristics of SARS-CoV-2 mRNA/LNP vaccines and their official verification Hanada Kentaro
11 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 SARS-CoV-2 research using stem cell and organ-on-a-chip technologies Takayama Kazuo
12 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 Establishment of SARS-CoV-2 respiratory tract infection model in CAG promoter-driven hACE2 transgenic mice Utsumi Daichi, Masamitsu Asaka, Haruhiko Kamada, Satoshi Nagata, Yutaka Nakachi, Tomokazu Yamaguchi, et al. (+3)
13 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mar―20 Development of artificial antibody against receptor binding domain of SARS-CoV-2 spike protein. Masahiro Oike, Hirotaka Takahashi, Tatsuya Sawasaki
14 [GO] Folia Pharmacologica Japonica 2022―Feb―28 Role of ACE2 in COVID-19 Yumiko Imai
15 [GO] Folia Pharmacologica Japonica 2022―Feb―28 Engineered ACE2 receptor has a potential for a new therapy of COVID-19 Yumi Itoh, Hajime Enatsu, Akira Takada, Toru Okamoto
16 [GO] Folia Pharmacologica Japonica 2022―Feb―28 Development of COVID-19 drugs using human iPS cell technology Shigeru Yamada, Yasunari Kanda
17 [GO] Folia Pharmacologica Japonica 2022―Feb―28 Eco-pharma research aimed at developing COVID-19 therapeutic agent Yuri Kato, Kazuhiro Nishiyama, Akiyuki Nishimura, Motohiro Nishida
18 [GO] Folia Pharmacologica Japonica 2022―Feb―28 Drug screening for COVID-19 using supercomputer “Fugaku” Yasushi Okuno
19 [GO] Folia Pharmacologica Japonica 2021―Dec―31 COVID-19 drug candidate pipeline, an overview Hiroyuki Sugiyama
20 [GO] Folia Pharmacologica Japonica 2021―Dec―31 Remdesivir for COVID-19 Yasuhisa Fujita
21 [GO] Folia Pharmacologica Japonica 2021―Dec―31 Drug repositioning to combat COVID-19 using artificial intelligence system Norihisa Shindo, Hiroyoshi Toyoshiba
22 [GO] Folia Pharmacologica Japonica 2021―Dec―31 Contribution to development of remedies for COVID-19: focusing on Eritoran Kappei Tsukahara
23 [GO] Folia Pharmacologica Japonica 2021―Oct―31 Responses to the COVID-19 pandemic and its impacts on pharmacology education in the universities and colleges in Japan: nationwide emergency survey jointly conducted by the Physiological Society of Japan and the Japanese Pharmacological Society Masaki Mogi, Tomoyuki Furuyashiki, Kazuhiro Takuma, Ken-ichi Otsuguro, Satoshi Tanaka, Masabumi Minami
24 [GO] Folia Pharmacologica Japonica 2021―Apr―30 Therapeutic potential of nanocurcumin in COVID-19 Koji Teshima
25 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Construction of the multi-layer omics data generation / analysis platform that contributes to the precision medicine of COVID-19 Yumiko Imai
26 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Treatment of COVID-19 Kazuhiro Yatera
27 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Remdesivir for COVID-19 Yasuhisa Fujita
28 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 COVID-19 Drug Candidate Pipeline, An Overview Hiroyuki Sugiyama
29 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Suppression of SARS-CoV-2-induced lung injury by ACE2-like carboxypeptidase B38-CAP in COVID-19 mouse model Tomokazu Yamaguchi, Takafumi Minato, Midori Hoshizaki, Masamitsu Asaka, Satoru Nirasawa, Mayumi Niiyama, et al. (+10)
30 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Nationwide Emergency Survey Results on the Response to COVID-19 Pandemic and Its Effect on Pharmacological Education Conducted in the Department of Pharmacology in Universities and Colleges Jointly by the Physiology Society of Japan and the Japanese Pharmacological Society. Masaki Mogi, Tomoyuki Furuyashiki, Kazuhiro Takuma, Ken-ichi Otsuguro, Tomoyuki Tanaka, Masabumi Minami
31 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Eco-pharma research aimed at developing COVID-19 therapeutic agent Kato Yuri, Motohiro Nishida
32 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Drug repositioning to combat COVID-19 using artificial intelligence system Norihisa Shindo, Hiroyoshi Toyoshiba
33 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Drug Screening for COVID-19 using Supercomputer "Fugaku" Yasushi Okuno
34 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Contribution to Development of Remedies for COVID-19: Focusing on Eritoran Kappei Tsukahara
35 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mar―20 Investigation of genetic variants in SARS-CoV-2-interacting molecules of ACE2, TMPRSS2 and TLR3/7/8 across populations Lee Ji-Won, In-Hee Lee, Sek Won Kong, Tadahiro Iimura
36 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2020―Mar―17 Treatment to prevent the development of severe COVID-19 Yumiko Imai
37 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2020―Mar―17 In silico approaches to drug repositioning for COVID-19 at AMED-BINDS Takatsugu Hirokawa, Sekijima Masakazu, Shigenori Tanaka, Haruki Nakamura
38 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2020―Mar―17 Nonstructural proteins of Novel Coronavirus (SARS-CoV-2) Wataru Kamitani
39 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2020―Mar―17 The initial response of the laboratory diagnosis team to SARS-CoV-2 in Japan and the current situation Makoto Takeda
 [1] 

39 Results       Page 1




[de][en]

Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.005 sec